The 3rd Annual European NeoAg Summit is the leading industry-dedicated meeting focused on advancing personalised cancer immunotherapy through neoantigen targeting.
Over the last year, there has been a record number of neoantigen-based therapies heading into and through the clinic. In addition, exciting collaborations that bring significant investment into the space means that tumour-specific antigen targeting is set to explode.
At the European NeoAg Summit, we bring together the leading pharma and biotech companies to discuss:
-Reducing the discordance between various neoantigen prediction methods-Maximising the immune response to neoantigens-Shortening the needle-to-needle time of personalised cancer immunotherapy-Navigating the evolving regulatory landscape to faster approval
Join the leaders from BioNTech, Genentech, Genocea, Gritstone Oncology, Agenus, Ziopharm, Vaccibody, the European Medicines Agency and many more to spur on more efficacious personalised cancer vaccines and cell therapies.
Conference + 2 Workshops: EUR 3397.0
Conference + 1 Workshop: EUR 2898.0
Conference only: EUR 2399.0
Workshop Only (Each): EUR 599.0
Speakers: John Castle, Associate Vice President, Head of Translational Medicine and Bioinformatics, Agenus, Andrew Ishizuka, Chief Scientific Officer, Avidea Technologies, Mathias Vormehr, Head of Cancer Vaccines, BioNTech, Michal Bassani-Sternberg, Sternberg Director, Immunopeptidomics Unit Center of Experimental Therapeutics, CHUV, Asterios Tsiftsoglou, Committee for Advanced Therapies Member, European Medicines Agency, Lélia Delamarre, Senior Scientist, Cancer Immunology Research, Genentech, Jessica Flechtner, Chief Scientific Officer, Genocea, Jennifer Busby, Senior Director of Mass Spectrometry and Proteomics, Gritstone Oncology, Norbert Hilf, Director of Translational Development, Immatics, John Wang, Chief Executive Officer, IOVaxis, Trevor Clancy, Chief Scientific Officer, OncoImmunity, Sean Boyle, Director, Bioinformatics Applications, Personalis, Agnete Fredriksen, Chief Scientific Officer, Vaccibody, Laurence Cooper, Chief Executive Officer, Ziopharm, Hans Keirstead, Chief Executive Officer, AIVITA Biomedical, Michael Stein, Executive Chairman, Valo Therapeutics, Anna Pasetto, Assistant Professor, Karolinska Institutet
Time: 8:00 am - 5:00 pmmore
- Highly Potent Active Pharmaceutical Ingredients (HPAPI) The HPAPI global market has developed rapidly in the past year an...
- 2019 8th Digital Marketing for Medical Devices West Built on a foundation of seven years of timely and informative co...
- Malvern Instruments Ltd Malvern supplies biophysical characterisation instruments, materials and expertise for pharmaceutica...
- Industry Leading Experts in a Global Pharmaceutical Industry – Providing you with Solutions across the Product Life Cycle NSF Health Sciences Pharma Biotech Consulting provides a comprehensive range of support services for...